Enhanced Differentiation of Bland and Neoplastic Portal Vein Thrombosis Using Photon-Counting CT
Overview
This study demonstrates that iodine density (ID) measurements obtained via photon-counting detector CT (PCD-CT) significantly improve differentiation between bland and neoplastic portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC) and other malignancies. The portal venous phase (PVP) was identified as the optimal contrast-enhanced phase for ID-based discrimination, offering high sensitivity and specificity without additional radiation exposure.
Background
Hepatocellular carcinoma (HCC) frequently involves macrovascular invasion, with neoplastic portal vein thrombosis (PVT) occurring in up to 40% of patients and strongly influencing prognosis and treatment. Differentiating neoplastic from bland PVT is clinically critical but challenging due to overlapping imaging features and risks associated with biopsy. While MRI is the gold standard for differentiation, its limitations necessitate reliance on CT imaging. Photon-counting detector CT (PCD-CT) offers spectral imaging with iodine quantification in every scan, potentially enhancing PVT characterization without increased radiation dose.
Data Highlights
Group
Number of Patients
Key Findings
HCC with Neoplastic PVT
n (not specified)
Higher iodine density values in PVP phase
HCC with Bland PVT
n (not specified)
Lower iodine density values in PVP phase
Non-HCC Malignancies with Neoplastic PVT
n (not specified)
ID measurements showed adequate sensitivity
Bland PVT without Malignancy
n (not specified)
Low iodine density values
Key Findings
Photon-counting detector CT enables iodine density quantification in all scans without preselection or additional radiation.
Iodine density measurements in the portal venous phase provide superior differentiation between bland and neoplastic PVT compared to other phases.
Absolute iodine density thresholds can reliably distinguish neoplastic from bland PVT in patients with HCC.
ID measurements also demonstrate adequate sensitivity for detecting neoplastic PVT in malignancies other than HCC.
Integrated assessment combining CT features and iodine quantification improves diagnostic confidence and may reduce the need for invasive biopsy.
Clinical Implications
Incorporating iodine density quantification from PCD-CT into routine imaging protocols can enhance noninvasive differentiation of bland versus neoplastic PVT, guiding appropriate treatment decisions in HCC and other malignancies. The portal venous phase is recommended for iodine quantification to optimize diagnostic accuracy. This approach may reduce reliance on MRI and invasive procedures, benefiting patients with contraindications or limited access to MRI.
Conclusion
Photon-counting detector CT with iodine quantification in the portal venous phase is a promising tool for accurately distinguishing bland from neoplastic portal vein thrombosis, supporting improved clinical management of patients with HCC and other cancers.
References
Ascenti et al. -- Iodine quantification in late arterial phase for PVT differentiation
Qian et al. -- Portal venous phase iodine density in PVT assessment
European Association for the Study of the Liver/American Association for the Study of Liver Diseases -- HCC diagnostic criteria
